Shinji Takeuchi

3.6k total citations
100 papers, 2.1k citations indexed

About

Shinji Takeuchi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Shinji Takeuchi has authored 100 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Pulmonary and Respiratory Medicine, 56 papers in Oncology and 42 papers in Molecular Biology. Recurrent topics in Shinji Takeuchi's work include Lung Cancer Treatments and Mutations (54 papers), Lung Cancer Research Studies (18 papers) and PI3K/AKT/mTOR signaling in cancer (16 papers). Shinji Takeuchi is often cited by papers focused on Lung Cancer Treatments and Mutations (54 papers), Lung Cancer Research Studies (18 papers) and PI3K/AKT/mTOR signaling in cancer (16 papers). Shinji Takeuchi collaborates with scholars based in Japan, United States and Singapore. Shinji Takeuchi's co-authors include Seiji Yano, Tadaaki Yamada, Akira Nishimoto, Shigeki Nanjo, Takayuki Nakagawa, Kunio Matsumoto, Sachiko Arai, Kenji Kita, Koji Fukuda and Azusa Tanimoto and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Shinji Takeuchi

89 papers receiving 2.1k citations

Peers

Shinji Takeuchi

PRM

ONCOL

PFM

Laetitia Borsu United States

Belinda Cancilla United States

Vincenzo Damiano Italy

Shi‐Ming Tu United States

Zariana Nikolova Switzerland

Michael Lahn United States

Christina Selinger Australia

Élodie Vauléon France

John Winstanley United Kingdom

Mayshan Ghiassi United States

Laetitia Borsu United States

Shinji Takeuchi

924 ×0.9

PRM

626 ×0.6

586 ×0.6

ONCOL

378 ×1.2

208 ×0.8

PFM

Citations per year, relative to Shinji Takeuchi Shinji Takeuchi (= 1×) peers Laetitia Borsu

Countries citing papers authored by Shinji Takeuchi

Since Specialization

Citations

This map shows the geographic impact of Shinji Takeuchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shinji Takeuchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shinji Takeuchi more than expected).

Fields of papers citing papers by Shinji Takeuchi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shinji Takeuchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shinji Takeuchi. The network helps show where Shinji Takeuchi may publish in the future.

Co-authorship network of co-authors of Shinji Takeuchi

This figure shows the co-authorship network connecting the top 25 collaborators of Shinji Takeuchi. A scholar is included among the top collaborators of Shinji Takeuchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shinji Takeuchi. Shinji Takeuchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yamada, Tadaaki, Brian Chan, Wentao Huang, et al.. (2025). MA02.06 Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01. Journal of Thoracic Oncology. 20(10). S59–S59.

Terashima, Takeshi, Tatsuya Yamashita, Kuniaki Arai, et al.. (2024). Comprehensive genomic profiling for advanced hepatocellular carcinoma in clinical practice. Hepatology International. 19(1). 212–221. 3 indexed citations

Kotani, Daisuke, Atsuo Takashima, Takeshi Kato, et al.. (2024). Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program. Clinical Colorectal Cancer. 23(2). 174–182.e6. 3 indexed citations

Fujiwara, Yutaka, Yasutoshi Kuboki, Masayuki Furukawa, et al.. (2023). FIGHT‐102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies. Cancer Medicine. 12(9). 10597–10611. 7 indexed citations

Tanimoto, Azusa, Shingo Matsumoto, Shinji Takeuchi, et al.. (2020). Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK -Rearranged/ TP53 -Mutant NSCLC via Noxa Expression. Clinical Cancer Research. 27(5). 1410–1420. 38 indexed citations

Adachi, Yuta, Chiaki Suzuki, Azusa Tanimoto, et al.. (2020). Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report. BMC Cancer. 20(1). 156–156. 4 indexed citations

Wang, Rong, Tadaaki Yamada, Sachiko Arai, et al.. (2019). Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice. Molecular Cancer Therapeutics. 18(5). 947–956. 20 indexed citations

Fukuda, Koji, Shinji Takeuchi, Sachiko Arai, et al.. (2019). Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status. Cancer Research. 79(7). 1658–1670. 79 indexed citations

Takeuchi, Shinji, Tetsunari Hase, Shinobu Shimizu, et al.. (2019). Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer. Cancer Science. 111(2). 561–570. 28 indexed citations

10.

Nishiyama, Akihiro, Tadaaki Yamada, Kenji Kita, et al.. (2018). Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model. Clinical Cancer Research. 24(10). 2357–2369. 22 indexed citations

11.

Nanjo, Shigeki, Sachiko Arai, Wei Wang, et al.. (2017). MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR -mutant Lung Cancer. Molecular Cancer Therapeutics. 16(3). 506–515. 47 indexed citations

12.

Tanimoto, Azusa, Shinji Takeuchi, Sachiko Arai, et al.. (2016). Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR- Mutant Lung Cancer. Clinical Cancer Research. 23(12). 3139–3149. 71 indexed citations

13.

Yamada, Tadaaki, Joseph M. Amann, Koji Fukuda, et al.. (2015). Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma. Cancer Research. 75(19). 4188–4197. 17 indexed citations

14.

Ebi, Hiromichi, Isao Oze, Takayuki Nakagawa, et al.. (2014). Lack of Association between the BIM Deletion Polymorphism and the Risk of Lung Cancer with and without EGFR Mutations. Journal of Thoracic Oncology. 10(1). 59–66. 11 indexed citations

15.

Nakagawa, Takayuki, Shinji Takeuchi, Tadaaki Yamada, et al.. (2013). EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition. Cancer Research. 73(8). 2428–2434. 136 indexed citations

16.

Nakagawa, Takayuki, Shinji Takeuchi, Tadaaki Yamada, et al.. (2012). Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR -Mutant Lung Cancer. Molecular Cancer Therapeutics. 11(10). 2149–2157. 74 indexed citations

17.

Wang, Wei, Qi Li, Shinji Takeuchi, et al.. (2012). Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer. Clinical Cancer Research. 18(6). 1663–1671. 76 indexed citations

18.

Yamada, Tadaaki, Shinji Takeuchi, Junya Nakade, et al.. (2012). Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells. Clinical Cancer Research. 18(13). 3592–3602. 93 indexed citations

19.

Donev, Ivan, Wei Wang, Tadaaki Yamada, et al.. (2011). Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer. Clinical Cancer Research. 17(8). 2260–2269. 93 indexed citations

20.

Ogino, Hirokazu, Masaki Hanibuchi, Soji Kakiuchi, et al.. (2011). E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor. Molecular Cancer Therapeutics. 10(7). 1218–1228. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact